Interview with Dr. Damaj highlights Commercial Products for Men's and Women's
Health, Recent Company Milestones Achieved, and Long Term Domestic and International
Growth Strategy
SAN DIEGO,
CA / ACCESSWIRE / November 3, 2014 / Innovus Pharmaceuticals, Inc.
("Innovus Pharma" or the "Company"), www.innovuspharma.com, (OTCBB:INNV) today announced that the
interview of Dr. Bassam Damaj, President & Chief Executive Officer of the
Company, on Wide World of Stocks was broadcast on Friday October 31, 2014 into
more than 50 million homes nationwide over BizTV, BizTV Radio, and You Tube
America Networks.
In the
interview, Damaj highlighted the milestones achieved by the Company, its
growth, the commercial availability of its products, the signed commercial
partnerships and expansion into 28 international markets.
"It
was a pleasure to present to the viewers of Wide World of Stocks and to
continue to provide information about Innovus and our commercial products",
said Dr. Damaj.
The interview
can be viewed online on the Wide World of Stocks YouTube channel at http://wideworldofstocks.com/.
About Innovus Pharmaceuticals, Inc.
Headquartered
in San Diego, Innovus Pharma is an emerging leader in the OTC male and female
sexual dysfunction and vitality products. The Company generates revenues from
its lead products Zestra(R) for female arousal, and EjectDelay(TM) for premature
ejaculation, and has a total of four marketed products in this space including
Sensum+(TM) (for sales outside the U.S. only), Zestra(R) Glide and Vesele(R).
For
more information, go to www.innovuspharma.com.
INNOVUS PHARMA'S FORWARD-LOOKING
Safe Harbor
Statements under the Private Securities
Litigation Reform Act, as amended: with the exception of the historical
information contained in this release, the matters described herein contain
forward-looking statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a variety of
reasons that are outside the control of the Company, including, but not limited
to, receiving patent protection for any of its products, receiving approval or
to be compliant with the requirements of any relevant regulatory authority
relating to such products, to successfully commercialize its products and to
achieve its other development, commercialization, financial and staffing
objectives. Readers are cautioned not to
place undue reliance on these forward-looking statements as actual results
could differ materially from the forward-looking statements contained
herein. Readers are urged to read the
risk factors set forth in the Company's most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are
available from the SEC's website or without charge from the Company.
Innovus Pharma Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930
SOURCE: Innovus Pharmaceuticals, Inc.